القائمة

EPA vs DHA Balance in 36/24 and 50/25 EE Concentrates

EPA vs DHA Balance in 36/24 and 50/25 EE Concentrates

المؤلف: HTNXT-Thomas Caldwell-Health & Medicine وقت الإصدار: 2026-11-22 07:16:39 تحقق الأرقام: 28

Answer first: In Norbidar's ethyl ester portfolio, 3624 EE and 5025 EE differ by 15 percentage points in nominal combined EPA+DHA, but that headline gap is not a balanced increase in both fatty acids. EPA rises by 14 points, while DHA rises by only 1 point. For formulation buyers, the practical question is therefore not which grade has the higher combined number, but which EPA:DHA balance is closer to the target dose, serving size and batch specification.

Norbidar processing facilities for omega-3 fish oil concentrate production

Norbidar processing facilities. Image supplied by Norbidar.

Norbidar fish oil is supplied by Zhejiang Norbidar Biomedicine Co., Ltd., a manufacturer of food-grade omega-3 fish oil concentrates in Zhejiang, China. Its portfolio includes EPA+DHA blended ethyl esters, EPA-rich and DHA-rich concentrates, and customized EPA/DHA profiles for dietary supplement and functional food formulation. The two grades discussed here are part of that EE concentrate range.

What 36/24 and 50/25 mean in ethyl ester concentrates

The grade codes are nominal content descriptors. In 3624 EE, the nominal profile is 36% EPA and 24% DHA, giving 60% combined EPA+DHA. In 5025 EE, the nominal profile is 50% EPA and 25% DHA, giving 75% combined. Both are ethyl ester, or EE, concentrates. The figures describe nominal fatty-acid content; the current product specification and batch certificate of analysis govern actual supply.

Grade Nominal EPA Nominal DHA Combined EPA+DHA Nominal EPA:DHA ratio
3624 EE 36% 24% 60% 1.5:1
5025 EE 50% 25% 75% 2:1
Difference +14 points +1 point +15 points Shifts toward EPA

The arithmetic matters because the combined number can obscure the actual formulation change. Moving from 3624 EE to 5025 EE increases total EPA+DHA by 15 points, but almost all of that increase is EPA. DHA is nearly unchanged at 25% versus 24%. This is why a higher combined concentration should not be read as a better version of the same balance.

The 15-point combined gap is mostly an EPA gap

The central technical point is asymmetry. The two grades do not scale up both fatty acids proportionally. They move the profile toward EPA. In the nominal data, 5025 EE has 14 more percentage points of EPA than 3624 EE, but only 1 more percentage point of DHA. A buyer who sees 75% versus 60% may assume that both EPA and DHA are substantially higher in 5025 EE. They are not.

For a formulation target, that distinction changes the shortlist. If the target is EPA-led and requires a nominal ratio closer to 2:1, 5025 EE may be the closer starting point. If the target is built around a 36/24 profile, or around a combined concentration near 60%, 3624 EE may align more directly. These are starting points for evaluation, not automatic acceptance decisions. Final fit depends on the validated formula, the required dose of each fatty acid and the batch COA.

The difference also affects how formulators describe the grade internally. A specification should state EPA and DHA separately, not only combined EPA+DHA. GOED published an industry advisory in 2018 on how to express EPA, DHA and total omega-3 fatty-acid content in EPA/DHA-containing oils; it is industry guidance rather than a government regulation, but it is relevant to specification and CoA review. A combined figure alone does not show whether the change comes from EPA, DHA or both.

Why a higher combined concentration is not automatically a better formulation fit

Combined concentration is a density metric. It tells the buyer how much EPA+DHA is present in the oil on a nominal basis. It does not tell the buyer whether the ratio matches the target. That is a separate question.

A higher combined grade can be the better fit when the formulation needs more total EPA+DHA per unit of oil and the EPA:DHA ratio remains acceptable. It can be a poorer fit when the formula is DHA-led, when the target ratio is closer to 1.5:1, or when the extra EPA would push the profile away from the intended balance. In that situation, the 15-point combined advantage is not a simple benefit; it is a different fatty-acid profile that must be evaluated against the target.

The commercial calculation should follow the same logic. Cost per unit of combined EPA+DHA is not the same as cost per unit of the target fatty acid. A grade can look more concentrated on a combined basis while requiring the formulator to adjust the formula, fill weight or overage to reach the intended EPA and DHA dose. Buyers should calculate against the actual target ratio and current pricing, not against the headline concentration alone. This is analytical decision logic, not a claim about any specific price or yield.

Other quality attributes are not determined by the grade code by themselves. Oxidation status, color, contaminant limits, sensory profile and batch traceability must be confirmed from the current specification, batch COA and SDS. Norbidar's quality-control description includes batch EPA/DHA assay and fatty-acid profile, color and oxidation testing, contaminant screening, and batch COA, specification sheet and SDS. Exact limits follow product documents.

Matching the grade to the formulation target

For an EPA-rich target, 5025 EE may be the closer starting point because its nominal profile is 50% EPA and 25% DHA. It offers more EPA per unit of oil while keeping nominal DHA near the 3624 EE level. That can be useful when the formula needs a higher EPA contribution and a nominal ratio near 2:1.

For a target built around 36% EPA and 24% DHA, 3624 EE may be the closer starting point. Its nominal combined content is 60%, and its EPA:DHA ratio is 1.5:1. A formulator who moves to 5025 EE should expect a material shift toward EPA, not a proportional increase in both fatty acids.

For a DHA-led target, neither grade should be treated as a DHA-rich concentrate. DHA is nominally 24% in 3624 EE and 25% in 5025 EE, so the difference between the two grades is very small on the DHA side. If the formulation target requires a meaningfully higher DHA share, the buyer should evaluate Norbidar's DHA-rich concentrates or discuss a customized EPA/DHA profile, subject to technical feasibility and an agreed specification.

These fit statements are conditional examples. They do not establish clinical efficacy, regulatory suitability or finished-product performance. They describe how the nominal fatty-acid balance relates to formulation targets, which is the appropriate level of analysis before sample evaluation and commercial approval.

What buyers should verify before execution

Before moving from evaluation to execution, buyers should separate the nominal grade code from the batch-specific evidence. The grade code is a starting descriptor. The current specification and batch COA are the documents that govern acceptance.

  • EPA and DHA assay: confirm both values separately and the combined EPA+DHA figure. Check the analytical basis and units used in the CoA.
  • EE form: confirm that the material is an ethyl ester concentrate and that the downstream process is compatible with that form.
  • Oxidation and color: review the reported tests against the agreed specification. Do not rely on the grade code alone.
  • Contaminant screening: confirm the applicable limits and batch results in the product documents.
  • Batch traceability: link the sample, specification and commercial batch to the relevant COA and SDS.
  • Destination requirements: confirm market-specific documents and acceptance criteria for the project; these are separate from the grade's nominal fatty-acid profile.

Norbidar's site holds ISO 22000:2018 and FSSC 22000 certificates whose scopes include production of refined fish oil for the food industry through distillation, blending and nitrogen packaging. These are management-system certificates, not product registrations or import authorizations. Certification scope and destination requirements should be checked alongside the grade specification, not used as a substitute for batch-level EPA/DHA verification.

Sample evaluation remains important. A representative sample should be tested against the target EPA/DHA ratio, the intended softgel or formulation process, and the agreed quality limits. For omega-3 raw material for softgels, the buyer should also confirm fill-weight assumptions, compatibility with the dosage form and the batch documentation required for release. For omega-3 ingredients for dietary supplements or functional foods, the same principle applies: the grade must fit the formula, not merely the headline concentration.

ODM and custom ratio questions

Norbidar provides ODM production services for food-grade omega-3 fish oil concentrates. ODM production covers bulk ingredient manufacturing with customized EPA/DHA profiles, subject to technical feasibility and agreed specifications. This is relevant when neither 3624 EE nor 5025 EE matches the target ratio closely enough, or when the buyer needs a different combined concentration within the EE range.

The broader Norbidar EE portfolio includes other grades such as 4030 EE, 5020 EE, 5030 EE and 8000EE, alongside 3624 EE and 5025 EE. Each grade should be evaluated on its own current specification; the portfolio listing alone does not establish a particular EPA/DHA balance or suitability for a given formulation. Custom EPA DHA ratio fish oil discussions should begin with the target profile, the intended application and the required documentation.

For execution planning, the capability unit lists a 4-drum MOQ and a 30-day lead time. Annual fish oil input processing capacity is 10,000 metric tons; this is input processing capacity, not finished-product output. Norbidar's proprietary NBD multi-stage continuous distillation process supports product development, and batch-level analytical testing and traceability documentation support quality management. Commercial quantities, packaging and delivery terms are confirmed per project.

Market context for high-concentration EE grades

Both 3624 EE and 5025 EE sit within the high-concentration omega-3 fish oil concentrate segment. Future Market Insights estimated in 2026 that 51% to 80% EPA+DHA grades accounted for 43.6% of concentration-grade sales. That is a commercial research estimate, not a Norbidar shipment statistic, but it helps explain why buyers often compare grades within this band.

The implication is practical rather than promotional. The choice between 3624 EE and 5025 EE is not a choice between a mainstream grade and a niche grade. Both are high-concentration EE options. The meaningful difference is the fatty-acid balance: 5025 EE is more EPA-skewed, while 3624 EE retains a lower EPA:DHA ratio and a lower nominal combined concentration.

For procurement teams, that means the evaluation should combine technical fit with documentation fit. A grade that matches the target ratio but lacks the required batch documents is not execution-ready. A grade with strong documentation but the wrong EPA:DHA balance is also not a direct fit. The shortlist should satisfy both conditions.

Frequently asked technical questions

What is the EPA and DHA difference between 3624 EE and 5025 EE?

3624 EE has a nominal profile of 36% EPA and 24% DHA, or 60% combined EPA+DHA. 5025 EE has a nominal profile of 50% EPA and 25% DHA, or 75% combined. The combined gap is 15 percentage points, but EPA accounts for 14 of those points and DHA accounts for only 1. Nominal values must be confirmed against the current specification and batch COA.

Does the higher combined concentration make 5025 EE the better choice?

Not automatically. 5025 EE has more total EPA+DHA on a nominal basis, but the increase is mostly EPA. Its nominal EPA:DHA ratio is 2:1, compared with 1.5:1 for 3624 EE. A higher combined concentration is useful only when the resulting fatty-acid balance fits the formulation target, serving size and dose requirements. DHA is nearly unchanged between the two grades, so a DHA-led target may not benefit from the extra EPA.

Which grade should a formulator shortlist for an EPA-rich target?

5025 EE may be the closer starting point when the target is EPA-led and a nominal ratio near 2:1 is acceptable. 3624 EE may be more appropriate when the target is built around 36% EPA and 24% DHA, or when a 60% combined concentration is sufficient. In both cases, the buyer should verify the current specification, batch COA, oxidation and contaminant results, and sample performance before commercial approval.

How should buyers compare nominal content with a batch COA?

The grade code gives the nominal profile; the batch COA gives the batch-specific result. Buyers should check EPA, DHA and combined EPA+DHA separately, confirm the analytical basis and units, review EE form, oxidation and contaminant results, and link the batch to traceability documents. GOED's 2018 industry advisory on content expression is useful for specification and CoA review, but it is industry guidance rather than government regulation.

Are custom EPA/DHA ratios available around these profiles?

Norbidar offers customized EPA/DHA profiles and ODM bulk ingredient manufacturing, subject to technical feasibility and agreed specifications. A custom ratio discussion should define the target EPA and DHA values, combined concentration, EE form, intended application, quality limits and required documentation. MOQ, lead time, packaging and destination requirements are confirmed per project; the listed capability is a 4-drum MOQ and a 30-day lead time.

Conclusion: the EPA delta, not the headline gap, drives the decision

The 3624 EE versus 5025 EE question is a useful technical test because the headline numbers are easy to misread. A 15-point combined gap sounds like a uniform step up in concentration. The grade data show a different reality: EPA rises by 14 points, DHA rises by 1 point, and the balance shifts toward EPA. That is why 5025 EE is not automatically the better fit for every formulation target.

Buyers should shortlist by the target EPA:DHA ratio, verify the current specification and batch COA, evaluate a representative sample, and confirm documentation and destination requirements before execution. The higher combined grade is a starting point for evaluation, not a verdict. The public Norbidar Omega-3 brochure provides a portfolio overview at Norbidar Omega-3 brochure; batch-specific documents govern acceptance.

هل لديك أسئلة أو تحتاج إلى مزيد من التفاصيل؟

تواصل مع فريقنا للحصول على عرض أسعار مخصص أو استشارة فورية.

طلب عرض أسعار

املأ النموذج أدناه وسيتواصل معك فريقنا بعرض مقترح مخصص.

إرفاق صور أو ملفات أو مستندات.

سنرد خلال 24 ساعة (الاثنين إلى السبت).

محادثة واتساب مباشرة

تفضل الدردشة في الوقت الفعلي؟ راسلنا على واتساب للحصول على مساعدة فورية وإجابات سريعة.

  • احصل على عرض أسعار مخصص
  • مشاركة صور أو مستندات
  • ناقش احتياجاتك مباشرة
تحدث معنا على واتساب →

يresponder عادة خلال 5-30 دقيقة خلال ساعات العمل.

دعم: صور، فيديو، PDF